Laboratory testing is one of the highest-volume services in American medicine, and one of the most frequently miscoded. A single tube of blood can support a diagnosis, guide a medication dose, or clear a patient for surgery. Each of those uses depends on a claim that links the right test to the right reason.

This article covers how blood tests are billed, what laboratories measure in each component of blood, and why those results matter to patient care. It also reviews the therapies built on human blood, the risks blood carries in modern medicine, and the steps patients and practices can take to stay protected.

Blood Test Billing Fundamentals

A blood test claim has two parts: the collection of the specimen and the laboratory analysis itself. Each part is coded separately, and each must be supported by an order and a diagnosis that establishes medical necessity.

Specimen Collection

Venipuncture is reported with CPT 36415, collection of venous blood by venipuncture. It is reported once per patient encounter, regardless of how many tubes are drawn or how many tests are ordered. Capillary collection by finger, heel, or ear stick is reported with 36416, which Medicare bundles into other services and does not pay separately. Code 99000 for specimen handling and transport is also generally not separately payable under Medicare, and commercial payer policies vary.

Common Blood Test Codes

CPT	Description	Typical Use
85025	Complete blood count (CBC) with automated differential	Anemia, infection, bleeding, baseline screening
85027	CBC without differential	Hemoglobin and platelet follow-up
80048	Basic metabolic panel (BMP)	Electrolytes, kidney function, glucose
80053	Comprehensive metabolic panel (CMP)	BMP plus liver function and proteins
80061	Lipid panel	Cholesterol and triglyceride assessment
83036	Hemoglobin A1c	Diabetes diagnosis and control
84443	Thyroid stimulating hormone (TSH)	Thyroid disorders
85610	Prothrombin time (PT/INR)	Warfarin monitoring, preoperative clotting
85730	Partial thromboplastin time (PTT)	Heparin monitoring, bleeding disorders
80076	Hepatic function panel	Liver disease, medication toxicity

Panel Coding Rules

When every component of an organ or disease panel is performed, the panel code must be reported rather than the individual component codes. Billing components separately when a panel applies is unbundling and draws payer edits and audit attention. Tests performed in addition to a complete panel are reported separately with their own codes. When only some components of a panel are ordered, each component is reported individually.

Medical Necessity and Diagnosis Linkage

Every laboratory line must link to an ICD-10-CM code that supports the reason for the test. In the outpatient setting, coders report confirmed diagnoses or the signs and symptoms that prompted the order; “rule out” and “suspected” conditions are not coded. Useful supporting codes include Z79.01 for long-term anticoagulant use with INR monitoring, Z51.81 for therapeutic drug level monitoring, Z01.812 for preprocedural laboratory examination, and the R70 through R79 range for abnormal blood findings.

Medicare applies national coverage determinations (NCDs) for many common laboratory tests, supplemented by local coverage determinations (LCDs). When a test is expected to fall outside covered diagnoses or frequency limits, an Advance Beneficiary Notice (ABN) should be signed before the draw, and the claim line is reported with modifier GA.

Screening Versus Diagnostic Testing

Screening tests are billed with screening diagnosis codes and follow frequency limits. Medicare covers cardiovascular screening blood tests (lipid panel and its components) once every five years using Z13.6. Diabetes screening glucose tests are covered up to twice a year for patients who meet risk criteria. Once a patient has a sign, symptom, or diagnosis, the test becomes diagnostic and is coded to that condition instead.

Modifiers for Laboratory Services

• QW: identifies a CLIA-waived test performed under a Certificate of Waiver.
• 90: reports a test sent to an outside reference laboratory when the practice bills for it, where payer rules permit.
• 91: identifies a repeat clinical laboratory test performed on the same day to obtain subsequent results, not a rerun for equipment failure or specimen problems.
• 59 or XU: identifies a distinct service when an edit pairs two tests that were separately indicated.

CLIA and Order Requirements

Any site that performs testing on human specimens must hold a Clinical Laboratory Improvement Amendments (CLIA) certificate, and the certificate type limits which tests can be billed. Every test requires an order from a treating provider, and the medical record must show the provider’s intent to order it. Standing orders, custom panels, and “check all that apply” requisitions are frequent audit targets because they can generate tests no one specifically needed.

Blood Components and Laboratory Testing

Whole blood is roughly 55 percent plasma and 45 percent cells. Laboratories separate and measure these parts because each one reflects a different body system.

Red Blood Cells

Red blood cells (erythrocytes) carry oxygen from the lungs to tissues using the protein hemoglobin. Laboratories measure the red cell count, hemoglobin, hematocrit (the percentage of blood made up of red cells), and red cell indices such as mean corpuscular volume. These values identify anemia, blood loss, dehydration, nutritional deficiencies such as low iron or B12, and conditions that cause too many red cells. Blood typing and antibody screening, which are performed before transfusion and during pregnancy, also examine red cell surface markers.

White Blood Cells

White blood cells (leukocytes) defend the body against infection and abnormal cells. The CBC differential breaks them into five types:

• Neutrophils: first responders to bacterial infection; elevated counts suggest acute infection or inflammation.
• Lymphocytes: B cells and T cells that drive immune memory; changes point to viral illness, immune disorders, or some leukemias.
• Monocytes: clear debris and damaged cells; rise in chronic infection and inflammation.
• Eosinophils: respond to allergies and parasites.
• Basophils: release histamine in allergic reactions; rarely elevated.

A high total white count can signal infection, stress, or blood cancer. A low count can result from chemotherapy, autoimmune disease, or bone marrow problems and leaves a patient vulnerable to infection.

Platelets

Platelets (thrombocytes) are cell fragments that plug damaged vessels and start clot formation. A platelet count identifies bleeding risk when low and clotting risk when high. Coagulation studies such as PT/INR, PTT, and fibrinogen measure how well the clotting proteins in plasma work alongside platelets.

Plasma

Plasma is the yellow liquid that carries everything else. It is about 90 percent water and holds the substances measured in most chemistry panels:

Plasma Substance	Example Tests	Clinical Purpose
Electrolytes (sodium, potassium, chloride, bicarbonate, calcium)	BMP, CMP	Fluid balance, heart rhythm, kidney and acid-base status
Glucose	Glucose, hemoglobin A1c	Diabetes diagnosis and control
Waste products (BUN, creatinine, bilirubin)	BMP, CMP, hepatic panel	Kidney and liver function
Proteins (albumin, globulins)	CMP, protein electrophoresis	Nutrition, liver disease, immune disorders, myeloma
Lipids (cholesterol, triglycerides)	Lipid panel	Cardiovascular risk
Enzymes (ALT, AST, alkaline phosphatase, troponin)	Hepatic panel, cardiac markers	Liver injury, bone disease, heart attack
Hormones (TSH, T4, cortisol, hCG)	Thyroid panel, pregnancy test	Endocrine disorders, pregnancy
Drug levels	Therapeutic drug monitoring	Safe dosing of medications such as vancomycin or lithium
Antibodies and antigens	Serology, hepatitis panel	Past or current infection, immunity, autoimmune disease

Serum is plasma after the blood has clotted and the clotting proteins have been removed. Many chemistry tests are run on serum, which is why some tubes are drawn with clot activators and others with anticoagulants.

Tests on the Whole Specimen

Some tests look beyond individual components. Blood cultures grow bacteria or fungi to confirm bloodstream infection and select an antibiotic. Genetic and molecular tests extract DNA from white cells to identify inherited conditions or tumor markers. Circulating tumor DNA testing, often called a liquid biopsy, searches plasma for fragments of cancer DNA.

Clinical Value of Blood Data

Blood reaches every organ, so it carries evidence of what is happening throughout the body. A few milliliters can reveal problems long before a patient feels symptoms.

• Diagnosis: Blood results confirm or exclude conditions such as diabetes, anemia, thyroid disease, kidney failure, and heart attack. A troponin level, for example, can distinguish a heart attack from other causes of chest pain within hours.
• Chronic disease monitoring: Serial results show whether treatment is working. Hemoglobin A1c reflects average blood sugar over roughly three months, and kidney function trends guide dialysis planning.
• Medication safety: Providers use blood levels to adjust doses of anticoagulants, antibiotics, seizure medications, and mood stabilizers. Liver and kidney panels detect drug side effects before they cause lasting harm.
• Screening and prevention: Cholesterol, glucose, and hepatitis screening find risk factors early, when lifestyle changes or treatment work best.
• Surgical readiness: Preoperative panels confirm that a patient can tolerate anesthesia and will clot normally during and after the procedure.
• Prognosis and treatment selection: Tumor markers and genetic tests help oncologists choose targeted therapies and track response.

For revenue cycle teams, this clinical value is also the basis for coverage. A payer pays for a blood test because the result changes what the provider does next, and the documentation should show that connection.

Blood-Based Therapies and Treatments

Blood is not only a diagnostic tool. Its cells and proteins are also used as medicine, either from donors or from the patient’s own body. These treatments work because blood already contains the oxygen carriers, clotting factors, immune proteins, and growth signals the body uses to heal.

Therapy	Blood Source	Purpose
Red blood cell transfusion	Donor	Restores oxygen delivery after blood loss, surgery, or severe anemia
Platelet transfusion	Donor	Prevents or stops bleeding in patients with low platelets, including chemotherapy patients
Plasma and cryoprecipitate	Donor	Replaces clotting factors in trauma, liver failure, and massive bleeding
Clotting factor concentrates	Pooled donor plasma or recombinant	Treats hemophilia and other inherited bleeding disorders
Albumin	Pooled donor plasma	Restores blood volume in shock, burns, and liver disease
Immune globulin (IVIG)	Pooled donor plasma	Supplies antibodies for immune deficiency and certain autoimmune and neurologic disorders
Autologous donation and cell salvage	Patient	Returns the patient’s own blood during or after surgery, avoiding donor exposure
Platelet-rich plasma (PRP)	Patient	Concentrated growth factors injected into tendons, joints, or chronic wounds
Stem cell and bone marrow transplant	Donor or patient	Rebuilds the blood and immune system after leukemia, lymphoma, or myeloma treatment
CAR T-cell therapy	Patient	Collected T cells are engineered to attack certain blood cancers, then reinfused
Therapeutic phlebotomy	Patient	Removes excess iron or red cells in hemochromatosis and polycythemia vera
Therapeutic apheresis	Patient	Filters harmful antibodies or cells from blood in conditions such as myasthenia gravis

Coding Considerations

These services carry their own coding rules and are frequent sources of denials. Transfusion administration is reported with 36430, and blood products are reported separately with HCPCS P codes by the facility that supplies them. Therapeutic phlebotomy is reported with 99195, and therapeutic apheresis falls in the 36511 through 36516 range. PRP injection is reported with Category III code 0232T, and most payers consider it investigational for orthopedic use, so an ABN or written financial waiver should be obtained before the procedure.

Risks Associated with Blood in Modern Medicine

The same qualities that make blood valuable also create risk. Blood can carry infection, trigger immune reactions, and produce results that are only as reliable as the process behind them.

Transfusion Reactions

Most transfusions are uneventful, but reactions do occur. Febrile and allergic reactions are the most common and are usually mild. Serious reactions include hemolytic reactions from mismatched blood type, transfusion-related acute lung injury (TRALI), and transfusion-associated circulatory overload (TACO), which strains the heart in older or fragile patients. Wrong-blood-in-tube errors at collection remain a leading cause of preventable mismatches.

Coding tips for transfusion complications. ICD-10-CM provides specific codes for most transfusion reactions, and accurate selection gives the transfusion committee reliable data on how often each reaction occurs.

Complication	ICD-10-CM
ABO incompatibility with acute hemolytic reaction	T80.310A
ABO incompatibility with delayed hemolytic reaction	T80.311A
Rh incompatibility with acute or delayed hemolytic reaction	T80.410A, T80.411A
Non-ABO incompatibility with acute or delayed hemolytic reaction	T80.A10A, T80.A11A
Febrile nonhemolytic transfusion reaction	R50.84
Anaphylactic reaction due to blood products	T80.51XA
Transfusion-related acute lung injury (TRALI)	J95.84
Transfusion-associated circulatory overload (TACO)	E87.71
Post-transfusion purpura	D69.51
Iron overload from repeated red cell transfusions	E83.111
Mismatched blood in transfusion (external cause)	Y65.0

• Code a complication only when the provider documents that the condition resulted from the transfusion. Fever, rash, or shortness of breath during a transfusion without that link warrants a provider query.
• Assign the seventh character by encounter: A for active treatment, D for subsequent care, S for sequela.
• Assign present on admission (POA) indicators carefully. ABO incompatibility that develops during the stay is a CMS hospital-acquired condition (HAC) and affects facility payment and public reporting.
• On inpatient claims, report the transfusion itself with the ICD-10-PCS administration code for the product given (for example, 30233N1 for nonautologous red blood cells into a peripheral vein) so reactions can be matched to the product.

Coding tips for cellular therapy complications. Stem cell transplant and CAR T-cell therapy carry their own complication codes. Stem cell transplant complications are reported with T86.5, and graft-versus-host disease with the D89.81- subcategory. Complications of CAR T-cell therapy are reported with T80.82XA, followed by the cytokine release syndrome grade from D89.83- and immune effector cell-associated neurotoxicity syndrome (ICANS) from G92.0- when documented.

Infection Transmission

Donor screening and testing have made transmission of HIV and hepatitis through the U.S. blood supply extremely rare. Bacterial contamination of platelets, which are stored at room temperature, is a larger remaining concern. Healthcare workers face bloodborne pathogen exposure through needlesticks and splashes, which is why OSHA requires exposure control plans and safety-engineered devices.

Coding tips for infection.

• Report T80.22XA for an acute infection following transfusion of blood or blood products, with additional codes for the specific infection and the organism (B95 through B97) when known.
• Report T80.211A for a central line-associated bloodstream infection. It is both a CMS HAC and an AHRQ Patient Safety Indicator, so the POA indicator must reflect the documentation exactly.
• Report R78.81 for bacteremia only when the provider documents it. When the provider states a positive blood culture was a contaminant, no infection code is assigned.
• For a staff needlestick, report exposure codes such as Z20.6 (HIV) or Z20.5 (viral hepatitis), with W46.0XXA or W46.1XXA for the needle and Y99.0 for work activity. These codes support workers’ compensation claims and OSHA sharps injury logs.

Laboratory Error

Most laboratory errors happen before the specimen reaches the analyzer. Mislabeled tubes, wrong tube types, delayed processing, and hemolyzed samples (red cells that burst during collection) can all produce false results. Some supplements interfere with testing as well; high-dose biotin can falsely raise or lower thyroid and troponin results.

Coding tips for laboratory error.

• Coders do not assign diagnoses from lab values alone. An abnormal result is coded only when the provider documents its meaning, and in the inpatient setting only when the provider indicates clinical significance.
• When a specimen is hemolyzed, clotted, or mislabeled and the test is redrawn, only one test is billed. Modifier 91 does not apply to reruns caused by specimen or equipment problems.
• Tracking redraw and cancellation reasons alongside claim data helps the laboratory find where collection errors originate.

Overtesting and Hospital Anemia

Routine daily labs in hospitalized patients can remove enough blood to cause anemia, sometimes leading to a transfusion that was never needed. Unnecessary tests also produce borderline results that lead to more tests, more procedures, and more cost without improving care.

Coding tips for overtesting and hospital anemia.

• Anemia is coded only when the provider documents it, and the type and cause should be clear. When hemoglobin drops during a stay and the record is silent, a provider query can clarify whether an acute blood loss anemia or another type is present.
• Laboratory CPT volume per patient day, by ordering provider or unit, gives utilization committees an accurate picture of testing patterns.
• Frequency edit denials are a signal worth reporting back to providers, since they often point to tests repeated without a new clinical reason.

Unproven and Fraudulent Services

Clinics market unproven blood-based treatments, including stem cell and PRP products for conditions they have not been shown to treat, often for large out-of-pocket fees. Laboratory fraud schemes, particularly around genetic and cancer screening, have targeted Medicare beneficiaries with “free” tests in exchange for their Medicare number and a cheek swab or blood draw. The Office of Inspector General has repeatedly warned about these schemes.

Coding tips for unproven and fraudulent services.

• Report PRP injection with 0232T. The code includes harvesting, preparation, and image guidance, so 20610, 76942, and similar codes are not added for the same injection.
• Never report a noncovered blood-based service under a covered code to secure payment. For Medicare patients, append GA when a valid ABN is on file or GX when a voluntary ABN was given for a statutorily noncovered service.
• Flag laboratory orders from providers with no treating relationship to the patient, especially for genetic and cancer screening panels. A spike in these orders is an early warning sign of a fraud scheme.

Billing and Data Exposure

Patients can receive surprise bills when a specimen is sent to an out-of-network laboratory without their knowledge. Genetic and blood data also carry privacy concerns, since this information can reveal inherited conditions that affect the patient’s relatives as well.

Coding tips for billing and data exposure.

• Verify that the performing laboratory on the claim matches the laboratory that actually ran the test, and use modifier 90 only where the payer permits the practice to bill for reference work.
• Limit genetic and blood test detail in claim notes and correspondence to what the payer requires to process the claim.

Coder Contributions to Safety and Quality Data

Coded data is often the first place a pattern of harm becomes visible. Hospitals, payers, and public agencies use ICD-10-CM and CPT codes to measure complications, rank facilities, and adjust payment. Coders strengthen that data in several ways.

• Specific code selection: A reaction coded to its exact type, rather than an unspecified code, tells the transfusion committee which products and processes need review.
• Accurate POA assignment: POA indicators separate conditions the patient arrived with from those that developed during the stay, which determines HAC penalties and Patient Safety Indicator results.
• Provider queries: Compliant, non-leading queries close documentation gaps when signs of a reaction or infection appear without a stated cause.
• Complication reports: Regular reports of T80 codes, CLABSI codes, and transfusion volumes by unit give quality and blood bank teams a starting point for hemovigilance review, including reporting to the CDC’s National Healthcare Safety Network where the facility participates.
• Education loops: Sharing coding findings with providers, nursing, and the laboratory turns individual claim corrections into process improvements that prevent the next error.

Patient Protection Guidance

Patients have more control over laboratory testing and treatment than most realize. A few questions and habits reduce both clinical and financial risk.

Before the Draw

• Ask the provider what each test is for and how the result will change treatment.
• Confirm fasting or medication instructions ahead of time.
• Tell the provider about all supplements, especially biotin, which is common in hair, skin, and nail products.
• Ask which laboratory will process the specimen and confirm that it is in network with the patient’s insurance.
• Medicare patients should read any ABN carefully before signing; it means Medicare may not pay for that test.

During the Draw

• Confirm that staff verify two identifiers, such as full name and date of birth, before drawing.
• Watch that tubes are labeled in the patient’s presence, not afterward at a desk.
• Ask whether a smaller-volume tube can be used when frequent draws are planned during a hospital stay.

After the Draw

• Request copies of results through the patient portal and keep a personal record to track trends.
• Ask about any result flagged high or low rather than waiting for a callback.
• Compare the Explanation of Benefits to the services received and question charges for tests that were not ordered.

Transfusion and Blood-Based Treatment

• For planned surgery, ask whether the hospital has a patient blood management program and whether autologous donation or cell salvage is an option.
• Know the patient’s blood type and any history of transfusion reactions.
• Before paying for stem cell, PRP, or other blood-derived injections, ask whether the treatment is FDA-approved for the condition and what evidence supports it.

Fraud Awareness

• Never give a Medicare or insurance number to someone offering free genetic or cancer tests by phone, at a health fair, or door to door.
• Only accept tests ordered by a treating provider the patient knows.
• Report suspected fraud to 1-800-HHS-TIPS or the Medicare fraud line at 1-800-MEDICARE.

Compliance Considerations for Practices and Laboratories

Blood test billing errors tend to come from the process, not from any one person. Practices can reduce denials and audit exposure by building checks into each step.

• Confirm that every test has a signed order and a documented reason in the provider’s note.
• Review requisition forms and standing orders at least annually so they do not prompt tests without a clinical need.
• Report panel codes whenever all components are performed, and review claim edits for unbundled components.
• Link each test to the diagnosis that supports it, coded to the highest specificity the documentation allows.
• Check NCD and LCD coverage lists for high-volume tests and train front-desk staff on when an ABN is required.
• Keep the CLIA certificate current and confirm the certificate type matches the tests performed in house.
• Use modifiers 90, 91, QW, and 59 only when documentation supports them.
• Audit a sample of laboratory claims each quarter and share findings with providers and staff.

Laboratory testing will keep growing as molecular and genetic testing expands. Practices that pair accurate coding with clear patient communication protect both their revenue and the patients they serve.

CPT codes, coverage limits, and payer policies change regularly. Readers should verify current code descriptors, NCDs, LCDs, and payer guidelines before applying this information to claims.